Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

NCT02833350 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

578

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: GDC-0853
DRUG: Adalimumab
DRUG: Folic Acid
DRUG: MTX
DRUG: Placebo

Sponsor

Genentech, Inc.